FZD2 and Robinow syndrome: Alternatively, targeted approaches may focus on downstream pathways such as in utero administration of DKK inhibitors in preclinical studies using humanized mouse models of FZD2 of Robinow syndrome, which showed ability to normalize skeletal growth (Liegel et al. 2023).